Overview
Tavin EM Tablets contain a fixed-dose combination of Tenofovir Disoproxil Fumarate (300 mg) and Emtricitabine (200 mg), both of which are nucleoside reverse transcriptase inhibitors (NRTIs). This once-daily oral formulation is commonly used as part of combination therapy for managing HIV-1 infection and is also recommended as pre-exposure prophylaxis (PrEP) in high-risk individuals. Tavin EM supports viral suppression and helps reduce the risk of transmission when used consistently under medical supervision.





